Grant: Undergraduate: Summer Studentship Award - Institute Community Support
McMaster University
$5,000.00
The Effect of Telmisartan on Muscle Inflammation in the Metabolic Syndrome: A Pilot Study
EF 2014-15
Résumé
ICS Studentship
Metabolic syndrome (MetS) is a combination of high blood pressure, high glucose levels, obesity, as well as high cholesterol levels. MetS affects over 34% of adults around the world, and places people at high risk of cardiovascular disease and type 2 diabetes. MetS-related obesity is associated with activation of the immune system in a process called 'inflammation'. Part of this inflammatory response is caused by immune system cells called macrophages, which migrate to skeletal muscle and other metabolic organs. These cells secrete substances called 'cytokines' that cause tissue inflammation and insulin resistance which is responsible for producing the high glucose levels found in MetS. Ideally, treatments of the MetS should target different components of MetS simultaneously. Telmisartan is a drug that is commonly used to lower blood pressure, but also has positive effects on metabolism by stimulating the PPAR gamma metabolic pathway, which is important in lipid metabolism in muscle. It is not known if Telmisartan improves muscle metabolism by preventing macrophages from entering muscle, or by making muscle release compounds that have anti-inflammatory effects. We are testing the theory that Telmisartan activates the anti-inflammatory response and lowers macrophages in muscle in MetS. This may allow the development of potential treatment to reduce muscle inflammation in MetS. The muscle samples used in the proposal are already collected from MetS patients who participated in a randomized clinical trial to test the effects of 6 months of Telmisartan therapy on intramyocellular fat content.
Programme
Undergraduate: Summer Studentship Award - Institute Community Support
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
323981
Name
Aditya Ishan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Summer Studentships in Musculoskeletal Health
Projecttitle
The Effect of Telmisartan on Muscle Inflammation in the Metabolic Syndrome: A Pilot Study
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$5,000
Cihrequipment2
$0
Programname2
Undergraduate: Summer Studentship Award - Institute Community Support
Keyworddelim
Anti-Inflammatory Response; Ics Studentship; Immune System; Immunohistochemistry; Inflammatory Cytokine; Macrophage; Metabolic Syndrome; Qrt-Pcr; Skeletal Muscle Inflammation; Telmisartan
Abstract
ICS Studentship
Metabolic syndrome (MetS) is a combination of high blood pressure, high glucose levels, obesity, as well as high cholesterol levels. MetS affects over 34% of adults around the world, and places people at high risk of cardiovascular disease and type 2 diabetes. MetS-related obesity is associated with activation of the immune system in a process called 'inflammation'. Part of this inflammatory response is caused by immune system cells called macrophages, which migrate to skeletal muscle and other metabolic organs. These cells secrete substances called 'cytokines' that cause tissue inflammation and insulin resistance which is responsible for producing the high glucose levels found in MetS. Ideally, treatments of the MetS should target different components of MetS simultaneously. Telmisartan is a drug that is commonly used to lower blood pressure, but also has positive effects on metabolism by stimulating the PPAR gamma metabolic pathway, which is important in lipid metabolism in muscle. It is not known if Telmisartan improves muscle metabolism by preventing macrophages from entering muscle, or by making muscle release compounds that have anti-inflammatory effects. We are testing the theory that Telmisartan activates the anti-inflammatory response and lowers macrophages in muscle in MetS. This may allow the development of potential treatment to reduce muscle inflammation in MetS. The muscle samples used in the proposal are already collected from MetS patients who participated in a randomized clinical trial to test the effects of 6 months of Telmisartan therapy on intramyocellular fat content.
Competitiondate
201501
Approvedterm2
0 yr 4 mths
Pinamesdelim
Aditya, Ishan
Approvedterm
0 an 4 mois
Cihrcontribution2
Inst of Musculoskel Hlth &Arth~ $5,000~ $0~